Skip to Content

Press Releases

Press Releases

Jan 02 2019
Intec Pharma Advances Medical Cannabinoid Development Program With Dosing of First Patient in a Phase 1 Pharmacokinetic Study of Accordion Pill-THC
Pursuing medical cannabinoids for a variety of pain indications JERUSALEM , Jan. 2, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces the dosing of the first patient in a Phase 1 pharmacokinetic (PK) study of AP-THC, its proprietary Accordion
Dec 19 2018
Intec Pharma Publishes Letter to Shareholders
Reviews 2018 progress and provides outlook for 2019 JERUSALEM , Dec. 19, 2018 /PRNewswire/ --    Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Jeffrey A. Meckler , Vice Chairman and Chief Executive Officer of Intec Pharma , has issued a Letter to Shareholders,
Dec 06 2018
Intec Pharma to Continue Development Collaboration to Next Phase
Accordion Pill for proprietary compound achieves in-vitro specifications Moving into clinical pharmacokinetic (PK) study in 2019 JERUSALEM , Dec. 6, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the Accordion Pill™ developed for a
Nov 09 2018
Intec Pharma Reports Third Quarter 2018 Financial Results and Corporate Update
Completed enrollment in pivotal Phase 3 ACCORDANCE trial; on track for topline data in mid-2019 JERUSALEM , Nov. 9, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the three and nine months ended September 30, 2018 and
Nov 06 2018
Intec Pharma to Participate in Upcoming November Investment Conferences
JERUSALEM , Nov. 6, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences in November.  H.C. Wainwright 2018 Annual Israel Conference Date: November 11, 2018
Oct 22 2018
Intec Pharma Completes Enrollment of Pivotal Phase 3 Clinical Trial of Accordion Pill™ Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients
On Track to Report Topline Data in Mid-2019 for Potential New Baseline Levodopa Treatment JERUSALEM , Oct. 22, 2018 /PRNewswire/ --  Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces the completion of patient enrollment in the Company's pivotal Phase 3 clinical trial
Sep 25 2018
Intec Pharma to Present Multiple Posters at International Congress of Parkinson's and Movement Disorder Society
JERUSALEM , Sept. 25, 2018 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that three posters in support of the Company's Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented at the upcoming
Sep 20 2018
Intec Pharma to Participate at Upcoming Investment Conferences

JERUSALEM , Sept. 20, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences.  Oppenheimer 2018 Fall Summit - Focused on Specialty Pharma and Rare Disease Date:

Aug 15 2018
Intec Pharma Reports Second Quarter 2018 Financial Results and Corporate Update

Enrolled more than 95% of patients in pivotal Phase 3 ACCORDANCE trial and more than 85% of eligible patients entered the open label extension study JERUSALEM , Aug. 15, 2018 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the

Jun 29 2018
Intec Pharma Appoints William Bradley Hayes to Board of Directors
Former LabCorp CFO Brings Wealth of Financial Experience JERUSALEM, June 29, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC) ("Intec" or "the Company") today announces the appointment of William Bradley Hayes (Brad) to the Company's Board of Directors.  Mr.
Displaying 11 - 20 of 87